In patients with T2D who had been hospitalized for poorly controlled blood glucose, SGLT2 inhibitors nearly doubled the risk ...

Expanding Medicare coverage for glucagon-like peptide 1 (GLP-1) receptor agonists could significantly reduce obesity-related ...

Pfizer has made the decision to discontinue the clinical development program for danuglipron, an oral GLP-1 receptor agonist, being investigated for chronic weight management.

Zepbound (tirzepatide) is a weekly injectable weight-loss medication. It can be purchased online or in person with a valid ...

"In this environment, it comes with a significant financial burden. We’re going to be in a loss position in 2025," Blue Cross ...

Experts express alarm that GLP-1 RAs may trigger or worsen eating disorders. But is there any role they might play in binge ...

Doctors have explained the potential pros and cons of these so-called 'skinny jabs', with everything from nausea to abdominal ...

Both glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) are associated with a reduced risk for Alzheimer disease and related dementias (ADRDs ...

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep medicine.

A U.S. study of over 500 youth aged 14–24 found high awareness but widespread hesitation about using semaglutide for weight ...

Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of science, technology, and medicine news ...